![Ross Moat](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ross Moat
Corporate Officer/Principal bij KINIKSA PHARMACEUTICALS, LTD.
Vermogen: 309 407 $ op 31-05-2024
Actieve functies van Ross Moat
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
KINIKSA PHARMACEUTICALS, LTD. | Corporate Officer/Principal | 01-02-2021 | - |
Loopbaan van Ross Moat
Eerdere bekende functies van Ross Moat
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
AVEXIS INC | Verkoop & Marketing | 01-05-2018 | 01-06-2019 |
SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | - | - |
Opleiding van Ross Moat
Middlesex University | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 4 |
Verenigd Koninkrijk | 2 |
Operationeel
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sales & Marketing | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Synageva BioPharma Corp.
![]() Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Novartis Gene Therapies, Inc.
![]() Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |